References
Nicoloso MS, Kipps TJ, Croce CM, Calin GA . MicroRNAs in the pathogeny of chronic lymphocytic leukaemia. Br J Haematol 2007; 139: 709–716.
Dijkstra MK, van Lom K, Tielemans D, Elstrodt F, Langerak AW, van 't Veer MB et al. 17p13/TP53 deletion in B-CLL patients is associated with microRNA-34a downregulation. Leukemia 2008, e-pub ahead of print.
Zenz T, Mohr J, Eldering E, Kater AP, Bühler A, Kiele D et al. Mir-34a as part of the chemotherapy resistance network in chronic lymphocytic. Blood 2008, e-pub ahead of print.
He L, He X, Lowe SW, Hannon GJ . microRNAs join the p53 network-another piece in the tumour-suppression puzzle. Nat Rev Cancer 2007; 7: 819–822.
Mott JL, Kobayashi S, Bronk SF, Gores GJ . mir-29 regulates Mcl-1 protein expression and apoptosis. Oncogene 2007; 26: 6133–6140.
Pekarsky Y, Santanam U, Cimmino A, Palamarchuk A, Efanov A, Maximov V et al. Tcl1 expression in chronic lymphocytic leukemia is regulated by miR-29 and miR-181. Cancer Res 2006; 66: 11590–11593.
O'Donnell KA, Wentzel EA, Zeller KI, Dang CV, Mendell JT . c-Myc-regulated microRNAs modulate E2F1 expression. Nature 2005; 435: 839–843.
Taguchi A, Yanagisawa K, Tanaka M, Cao K, Matsuyama Y, Goto H et al. Identification of hypoxia-inducible factor-1 alpha as a novel target for miR-17-92 microRNA cluster. Cancer Res 2008; 68: 5540–5545.
Acknowledgements
We acknowledge Prof Ivo Slapak (Department of Paediatric Otorhinolaryngology) for providing control samples after tonsillectomy, Dr Hana Skuhrova Francova (Center of Molecular Biology and Gene Therapy) for performing IgVH status analysis and Professor Petr Kuglik (Department of Medical Genetics) for FISH data. This work was supported by Research Grant IGA MZ CR NR9293-3/2007 provided by the Internal Grant Agency of the Ministry of Health in the Czech Republic.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Mraz, M., Malinova, K., Kotaskova, J. et al. miR-34a, miR-29c and miR-17-5p are downregulated in CLL patients with TP53 abnormalities. Leukemia 23, 1159–1163 (2009). https://doi.org/10.1038/leu.2008.377
Published:
Issue Date:
DOI: https://doi.org/10.1038/leu.2008.377
- Springer Nature Limited
This article is cited by
-
A miR-34a-guided, tRNAiMet-derived, piR_019752-like fragment (tRiMetF31) suppresses migration and angiogenesis of breast cancer cells via targeting PFKFB3
Cell Death Discovery (2022)
-
Evaluation of microRNA-223 and microRNA-125a expression association with STAT3 and Bcl2 genes in blood leukocytes of CLL patients: a case–control study
BMC Research Notes (2021)
-
Combination therapy with miR-34a and doxorubicin synergistically induced apoptosis in T-cell acute lymphoblastic leukemia cell line
Medical Oncology (2021)
-
RNA-Seq profiling of deregulated miRs in CLL and their impact on clinical outcome
Blood Cancer Journal (2020)
-
Emodin, a natural anthraquinone, suppresses liver cancer in vitro and in vivo by regulating VEGFR2 and miR-34a
Investigational New Drugs (2020)